#Japan #Tokyo #ALS #SOLA Biosciences #SOL-257

SOLA Biosciences Japan's Vision for ALS Treatment

SOLA Biosciences Japan, a wholly-owned subsidiary of Boston-based SOLA Biosciences Inc., has recently been chosen for the Japan Agency for Medical Research and Development's (AMED) initiative aimed at bolstering the drug venture ecosystem. With this approval, SOLA Japan will receive approximately 6 billion yen over a five-year period to advance the development of its lead candidate gene therapy, SOL-257. This project, announced by AMED on June 5, 2026, directly addresses the critical unmet medical needs of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

As a degenerative neurological disorder, ALS is characterized by the progressive loss of motor neurons, making its treatment a monumental challenge in the medical field. Approximately 97% of ALS cases have shown abnormalities related to the TDP-43 protein, which is associated with the disease's pathogenesis. These anomalies lead to a loss of TDP-43's natural function, contributing to neurodegeneration. Therefore, SOLA aims to restore the structure and function of this critical protein, offering hope to countless patients and their loved ones.

The Innovative SOL-257 Gene Therapy

SOL-257 is developed through SOLA's proprietary JUMP70 platform, which harnesses the body's innate protein quality control mechanisms. This innovative platform is designed to specifically identify misfolded proteins related to diseases while leaving normal proteins intact. By combining disease-specific targeting domains with those that activate the protein quality control mechanisms, JUMP70 mobilizes molecular chaperone HSP70 to restore and degrade faulty proteins effectively.

In the case of SOL-257, this approach is directed at misfolded TDP-43. The goal is to selectively recognize these faulty proteins and promote the recovery of their normal structure and function. This methodology directly addresses the common molecular pathology seen in most ALS cases, positioning SOL-257 as a potentially groundbreaking gene therapy for the treatment of ALS.

SOLA's strategy includes clinical proof of concept (POC) trials in both Japan and the United States, alongside establishing a foundation for global clinical development. The project is supported by Curie.Bio, an AMED-certified venture capital firm leading the investment, with contributions from Tokyo University Edge Capital Partners (UTEC) acting as a follow-on investor.

Leadership Commitment to ALS Research

Keizo Furuya, CEO and founder of SOLA Biosciences, expresses his gratitude for AMED's support, recognizing the immense responsibility that comes with developing SOL-257 efficiently and scientifically accurately. He emphasizes that time is of the essence for ALS patients and their families. The collaboration of researchers, clinicians, investors, manufacturing partners, and pharmaceutical companies across Japan and the United States will be crucial in advancing innovative treatments forthwith.

Yudai Inokuchi, COO of SOLA Biosciences Japan, also underscores the significance of this selection as a major opportunity to establish a unified development framework between Japan and the U.S. He stresses the importance of integrating Japan's strengths in science, clinical practice, and manufacturing with SOLA's global development expertise to transform innovative sciences into meaningful outcomes for patients.

About SOLA Biosciences Japan

SOLA Biosciences Japan integrates functions across Japan and the U.S. to address diseases with high unmet medical needs, including ALS. The company focuses on developing innovative gene therapies and next-generation pharmaceuticals by leveraging its strengths in science, clinical development, manufacturing, investment, and business development.

Note: SOL-257 is a gene therapy candidate that is still under development and has not yet received approval from any regulatory authorities, either domestically or internationally.